article thumbnail

Healthcare & Life Science M&A Activity Plummets 1H’22

HIT Consultant

What You Should Know: – The index of Healthcare & Life Science equities tracked by Stout was down 16.8% – Healthcare & Life Science M&A activity plummeted to 338 deals in Q2 2022 versus 535 in Q2 2021 and a record 565 deals in Q4 2021. Medical Device equities were down 18.5%

article thumbnail

How the Life Sciences Industry Can Boost Diversity and Inclusion Efforts

HIT Consultant

Although it is well established that diversity improves outcomes and drives excellence, implementing diversity lags behind in many industries, including life sciences and healthcare. The pharmaceutical industry differs in many ways from other industries. Other Steps Life Sciences Companies Can Take to Improve Diversity.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Servant Leadership at Its Finest: A Q&A With Life Science Leader, Liz Paulson

Lexis Nexis

The Healthcare Businesswomen’s Association (HBA) recognized Liz Paulson, LexisNexis® Risk Solutions Life Science Leader, with its prestigious STAR Award at its Woman of the Year luncheon on May 16, 2023. I decided to pursue work in pharmaceuticals next so I could help more than one individual at a time and have a greater impact.

article thumbnail

Insights Management: A New Paradigm for Cancer Treatment

HIT Consultant

Lance Hill, CEO of Within3 The cancer market for the pharma industry accounts for about a third of their product pipeline. With oncology drug sales set to top $390 billion by 2027 , life science companies are aligning efforts to prioritize this critical market opportunity ahead of competitors.

article thumbnail

Digiceuticals: Driving Growth Through Digital Health Services

HIT Consultant

Subhro Mallik, SVP & Head of Life Sciences at Infosys. The new normal has thrown up opportunities as well as risks for pharmaceutical companies. The application of digital technologies in pharmaceuticals – digiceuticals – is a promising way forward. There was tremendous interest in telemedicine before 2020.

article thumbnail

Why Health Tech Firms Must Hire Chief Medical Officers

HIT Consultant

They use their combination of experience in clinical, procedural and operational expertise to support the C-Suite directly and drive growth in industry verticals such as national population health initiatives, insurance and life sciences partnerships.

article thumbnail

JAPAC Drug Development: Navigating Safety & Regulatory Requirements

HIT Consultant

In fact, in 2018, 80% of all biopharma pipeline projects in JAPAC were EBPs, accounting for 75% of the total clinical trial volume in the region. They are also in communication with the sponsor, who is the MAH of the active pharmaceutical ingredient. In comparison to Japan, China has fewer distinctions.